Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q3 2021 · 10-Q
Revenue$24.04M$24.04M+226.4% vs Q3 2020 Net Income-$11.28M-$11.28MN/M vs Q3 2020 EPS Diluted-$0.19-$0.19N/M vs Q3 2020 Operating Income-$11,542,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$24,638,000N/M Margins · derivedOperating margin-48.0%+305.7 pt vs Q3 2020
Net margin-46.9%+306.4 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 10, 2021 · 41 d after period end